Company Overview
Boston Scientific makes medical devices used in a range of clinical procedures. The business sells products into healthcare providers, with demand tied to ongoing patient care rather than one-off projects. At its current scale, it operates as a large, established player in the health care space. The company’s footprint is reflected in a market capitalization of about USD 102.6 billion.
Analysis of recent data
FundamentalsFor 2025, reported in USD, revenue reached about USD 20.1 billion, alongside EBIT of roughly USD 3.6 billion and net income of about USD 2.9 billion. Revenue growth year over year was 19.9%, while trailing margins were 69.01% gross, 18.00% operating, and 14.44% net.
Cash stood at USD 2.0 billion against total debt of USD 11.1 billion at year-end. Depreciation and amortization were USD 1.4 billion, with capital spending of USD 876 million, bringing the company’s cash flow proxy to about USD 3.6 billion.
Valuation
DCF / MultiplesAt USD 69.17, the stock trades within the model’s fair-value range rather than at an edge. The pricing also comes with relatively full headline multiples, including a 35.41 P/E and 24.15 EV/EBITDA, framing the shares as a durability story the market is already willing to pay for.
Conclusion
TakeawayThe business looks built for repeat demand and steady cash generation. The current price still needs those economics to hold up. If margins fade or growth slows, the valuation can tighten quickly. Overall, the setup leans favorable, but not forgiving.